What is Ovaprene®?
Ovaprene® is an investigational monthly, hormone-free intravaginal contraceptive being developed by Daré Bioscience.
Yanuki
ARTICLE DETAIL
Daré Bioscience Ovaprene® Phase 3 Trial Shows Positive Results | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries | Daré Bioscience Ovaprene® Phase 3 Trial Shows Positive Results | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries
Health / Women's Health
Daré Bioscience Ovaprene® Phase 3 Trial Shows Positive Results
Daré Bioscience (NASDAQ: DARE) has announced positive interim results from its Phase 3 clinical trial evaluating Ovaprene®, a novel hormone-free, monthly intravaginal contraceptive. The trial data supports Ovaprene's potential as a meaningf...
Key Insights
- Interim Phase 3 results for Ovaprene® show a pregnancy rate consistent with company expectations, reinforcing its potential as a hormone-free contraceptive option.
- No new safety or tolerability concerns were identified during the interim analysis.
- Approximately 17% of participants discontinued the study due to vaginal odor, the most commonly reported adverse event.
- Daré Bioscience received a $6 million non-dilutive grant installment to support its smart drug delivery device.
- Bayer has the right to acquire exclusive U.S. commercialization rights to Ovaprene upon completion of the pivotal clinical trial, subject to a $20 million payment to Daré.
In-Depth Analysis
Daré Bioscience is focused on addressing unmet needs in women’s health through innovative solutions. Ovaprene® represents a potential first-in-category hormone-free monthly intravaginal contraceptive. The ongoing Phase 3 trial is a multicenter, single-arm, open-label study enrolling women aged 18–40 across 5 sites (clinicaltrials.gov: NCT06127199?ref=yanuki.com). Interim results showed that approximately 9% of women in the study experienced a pregnancy, aligning with expectations based on previous studies. Participants who completed the study indicated they would likely use Ovaprene if it became available. The company also received a $6 million grant installment supporting its smart drug delivery device, highlighting the potential for broader applications beyond contraception. Shares of Daré Bioscience surged following the announcement of these positive results.
FAQ
What were the key findings of the Phase 3 interim analysis?
The interim analysis showed a pregnancy rate consistent with company expectations, no new safety concerns, and favorable tolerability.
What is the potential market for Ovaprene®?
Millions of women in the U.S. are seeking effective, hormone-free birth control, suggesting a significant unmet need that Ovaprene could address.
What is the significance of the $6 million grant installment?
The grant supports the development of Daré Bioscience’s smart drug delivery device, which has potential applications in contraception, obesity, and metabolic disorders.
Takeaways
- Ovaprene® offers a potential hormone-free alternative for women seeking contraception.
- The Phase 3 trial results are promising and indicate good safety and tolerability.
- Daré Bioscience is also advancing innovative drug delivery technologies with broader health applications.
Discussion
Do you think hormone-free contraceptives like Ovaprene® will become more popular? Share your thoughts in the comments below!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.